17:03 , Oct 26, 2018 |  BC Week In Review  |  Financial News

Antibiotics play Qpex launches with Medicines Co. assets, BARDA deal

With $33 million in new series A funding, a portfolio of preclinical assets from The Medicines Co. (NASDAQ:MDCO) and a BARDA deal, Qpex Biopharma Inc. (San Diego, Calif.) hopes to begin clinical studies of multiple...
15:56 , Oct 26, 2018 |  BioCentury  |  Finance

Rempex remix

New Enterprise Associates led Qpex Biopharma Inc.’s $33 million A round in hope that the management team will repeat its performance at Rempex Pharmaceuticals Inc. and The Medicines Co. (NASDAQ:MDCO) with a preclinical anti-infectives portfolio....
12:02 , Oct 22, 2018 |  BC Extra  |  Financial News

Antibiotics play Qpex launches with Medicines Co. assets, BARDA deal

With $33 million in new series A funding, a portfolio of preclinical assets from The Medicines Co. (NASDAQ:MDCO) and a BARDA deal, Qpex Biopharma Inc. (San Diego, Calif.) hopes to begin clinical studies of multiple...
15:18 , Sep 1, 2017 |  BC Week In Review  |  Clinical News

FDA approves cUTI combo Vabomere from MDCO

FDA approved Vabomere meropenem/vaborbactam (Carbavance) from The Medicines Co. (NASDAQ:MDCO) to treat adults with complicated urinary tract infections (cUTI) including pyelonephritis caused by Escherichia coli , Klebsiella pneumoniae and Enterobacter cloacae species complex. The company...
21:06 , Aug 30, 2017 |  BC Extra  |  Company News

FDA approves cUTI combo from MDCO

After market close Tuesday, FDA said it approved Vabomere meropenem/vaborbactam from The Medicines Co. (NASDAQ:MDCO) to treat adults with complicated urinary tract infections (cUTI) including pyelonephritis caused by Escherichia coli , Klebsiella pneumoniae and Enterobacter...
08:00 , Jan 5, 2015 |  BioCentury  |  Finance

Back for more

About three years after closing its last fund, Vivo Capital (formerly Vivo Ventures) has come back for more. The firm raised $428 million for an eighth fund, according to a December SEC filing. Vivo invests...
08:00 , Nov 17, 2014 |  BC Week In Review  |  Clinical News

Carbavance: Phase III started

The Medicines Co. began the double-blind U.S. Phase III TANGO 1 trial to compare thrice-daily 2 g/2 g IV Carbavance vs. IV Zosyn tazobactam/piperacillin in about 850 adults with cUTIs or acute pyelonephritis. If necessary,...
08:00 , Nov 17, 2014 |  BC Week In Review  |  Clinical News

Carbavance: Phase III started

The Medicines Co. began the open-label U.S. Phase III TANGO 2 trial to compare thrice-daily 2 g/2 g IV Carbavance vs. the best available therapy with IV antibiotics for 14 days in about 150 adults...
07:00 , Jun 9, 2014 |  BioCentury  |  Finance

Banker tracks

Banker tracks Maarten de Jong will join Moelis & Co. (NYSE:MC) in August as a managing director focused on healthcare. de Jong was a managing director at Barclays plc (NYSE:BCS). Private equity tracks Sudhir Bahl...
08:00 , Feb 10, 2014 |  BC Week In Review  |  Company News

Medicines Co., U.S. Department of Health and Human Services (HHS) infectious news

HHS's Biomedical Advanced Research and Development Agency awarded The Medicines Co. a contract worth up to $90 million to develop Carbavance for serious Gram-negative infections as well as melioidosis and glanders, which are caused by...